CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine

CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine

Melbourne, Australia — 29/05/2009

CSL Limited (ASX:CSL), Australia’s leading biopharmaceutical company, announced today that its US subsidiary, CSL Biotherapies, Inc., has signed a contract with the U.S. Department of Health and Human Services (HHS) to provide Novel A (H1N1) influenza vaccine antigen in bulk form. The vaccine will be manufactured at CSL’s facility in Parkville, Victoria, and will support the HHS pre-pandemic influenza preparation efforts. The new vaccine will be tested in clinical trials funded by HHS. The initial order under the contract will be for an amount of USD180 million.


Download this release:
PDF icon CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government
         to Produce Novel Influenza A (H1N1) Vaccine
(0.36 MB)


Media Contact:Investor Contact:
Dr Rachel David
  Director, Public Affairs
  CSL Limited
  Telephone: +613 9389 1821
  Email: rachel.david@csl.com.au

Mark Dehring
  Head of Investor Relations
  CSL Limited
  Telephone: +613 9389 2818
  Email: mark.dehring@csl.com.au



© 2016 CSL Limited